Steatohepatitis/Metabolic Liver Disease News

A new model has projected a substantial rise in the burden of metabolic dysfunction-associated steatotic liver disease in the U.S. by 2050, which could be minimized by effective preventive and management strategies, researchers wrote.

Dry January has become an increasingly popular trend in which people abstain from alcohol use for 1 month to reset their health after the holiday season. But, for some, it could be a wake-up call about their struggles with alcohol.

Exposure to environmental chemicals during pregnancy may increase the risk for liver injury and steatosis in children and mothers, which could be mitigated by higher folic acid supplementation, according to a study in Journal of Hepatology.

From 2002 to 2021, the incidence rate of alcohol-associated hepatitis “more than doubled” among adolescents and young adults in Ontario, Canada, with the highest uptick observed among females, according to research in JAMA Network Open.

Midlife women with a metabolic dysfunction-associated steatotic liver disease diagnosis were more likely to report severe or very severe hot flashes, though researchers found no direct link between the two conditions, data show.

Endoscopic sleeve gastroplasty with lifestyle intervention was more effective than lifestyle changes alone in achieving weight loss and histological improvement in patients with metabolic dysfunction-associated steatohepatitis and obesity.

Hispanic patients hospitalized for alcohol use disorder were more likely to develop alcohol-associated hepatitis, decompensated cirrhosis and related complications compared with non-Hispanic white patients, according to published data.

SAN DIEGO — Both FibroScan-aspartate aminotransferase and Agile 3+ scores “performed well” in predicting risk for advanced fibrosis in patients with metabolic dysfunction-associated steatohepatitis who had been treated with pegozafermin.

SAN DIEGO — Once-daily ALG-055009 achieved “significant and robust reductions” in liver fat at 12 weeks and was well-tolerated among noncirrhotic patients with metabolic dysfunction-associated steatohepatitis, according to data.